Lupus & antiphospholipid syndrome
Tofacitinib versus thalidomide for mucocutaneous lesions of systemic lupus erythematosus: A real-world CSTAR cohort study XXVII
Authors' conclusion
Tofacitinib might be superior to thalidomide in the improvement of mucocutaneous and musculoskeletal lesions in SLE, and had a good safety profile.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients with mucocutaneous and/or musculoskeletal symptoms, Chinese SLE Treatment and Research group (CSTAR) registry
- Exposure
- Tofacitinib vs thalidomide
- Outcome
- Improvement in mucocutaneous and musculoskeletal lesions
- Follow-up
- 3 and 6 months
Methodological detailsreal-world, registry-based (CSTAR)
- Real-world
- Registry-based (CSTAR)
Main finding
As reported in the abstract
- Higher proportion of patients with improvement in mucocutaneous and musculoskeletal issues with tofacitinib
Observational data: associations, not effects.
Further findings
Remission or LLDAS · 3 and 6 months
- Greater percentage achieved remission or LLDAS with tofacitinib
Serological indicators
- No significant serological improvements in either group
Original publication
Tofacitinib versus thalidomide for mucocutaneous lesions of systemic lupus erythematosus: A real-world CSTAR cohort study XXVII. Lupus. Published 8 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →